The State Institute for Drug Control, abbreviated as SÚKL, is a Czech authority which, under the Public Health Insurance Act, carries out cost-effectiveness assessments of vaccines, known as health technology assessments (HTA).[1][2]
Assessment of vaccines
A manufacturer or its representative in the Czech Republic may apply to have a vaccine's benefit assessed and its reimbursement determined. SÚKL then prepares an assessment report evaluating, among other things, its effectiveness for healthcare as well as for the public health system.[1][2] At present, COVID-19 vaccines are covered by public health insurance for all who want them, while influenza vaccines are paid for by insurers for people over 65 years of age.[1]
Deputy Chief Hygienist Matyáš Fošum stated on 6 October 2026 that the Institute would use this same procedure to assess the COVID-19 vaccine, which the state will no longer provide from 2027. SÚKL will determine its possible reimbursement from public health insurance or the amount of any co-payment.[1][2] Minister of Health Adam Vojtěch (ANO) stated that the state will no longer provide COVID-19 vaccines from 2027 onward. For 2026, when deliveries under the original joint EU order come to an end, 900,000 doses will be available.[1]
Chronology
- — Minister of Health Adam Vojtěch announced on 6 October 2026 that from 2027 the state will no longer provide COVID-19 vaccines, and that their possible reimbursement from public health insurance will be assessed by the State Institute for Drug Control. → Czech News Agency / České noviny Echo24
Pages linking here
Sources
- ČTK / České noviny — 6 October 2026
- Echo24 — 6 October 2026